BNTC

NASD Benitec Biopharma Inc

Oct 31, 2026 · 4:58 AM ET EOD Market Closed

$8.74 ↑ +0.00 (+0.00%) Trading Up from the previous close of $8.74, $0.19 below the day’s high of $8.93

YTD change: -35.12%
vs 20-day SMA: +0.09%
vs 200-day SMA: -24.37%

Price ranges

Previous day

$8.43 $8.93

open $8.80 close $8.74

-$0.06 (-0.68%)

Today

$8.43 $8.93

$8.74

Past week

$7.89 $9.11

from $8.82 now $8.74

-$0.08 (-0.91%)

Past month

$7.89 $9.99

from $9.58 now $8.74

-$0.84 (-8.77%)

This year

$7.89 $14.33

from $13.47 now $8.74

-$4.73 (-35.12%)

Price & Performance

-3.21 (-26.86%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good

The stock is 99.1% away from all-time highs of $931.60
BNTC is down 35% since the beginning of the year
BNTC is down 46% over the past 12 months
BNTC is down 9% over the past 1 month
8% of all BNTC investors are betting against BNTC

BNTC reads not so good: price sits above one of the two key moving averages, the 12-month move is -46.6%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-0.26

Earnings momentum +5.5% Quarterly EPS growth

Quarterly change +5.5%

Valuation

P/E ratio N/A

Enterprise value $231.8M

Beta -0.75

Balance sheet & scale

IncomeN/A

RevenueN/A

Cash$180.1M

Debt$762.0

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Professional, Scientific, and Technical Services

Industry Group Scientific Research and Development Services

Market cap $304.9M

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. Its proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.

Competitor comparison

Ticker	Company	Price	Change
GNNSF	Genscript Biotech Corporation	$4.50	+5.88%
GLXY	Galaxy Digital Inc. Class A	$16.00	-11.75%
PVLA	Palvella Therapeutics, Inc.	$146.15	-3.58%
EPRX	Eupraxia Pharmaceuticals, Inc.	$6.83	-5.79%
CLRPF	Clarity Pharmaceuticals Ltd.	$1.15	-8.00%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.